Selective drug combination vulnerabilities in STAT3- and TP53-mutant malignant NK cells.

ABSTRACT: Mature natural killer (NK) cell neoplasms are rare but very aggressive types of cancers. With currently available treatments, they have a very poor prognosis and, as such, are an example of group of cancers in which the development of effective precision therapies is needed. Using both short- and long-term drug sensitivity testing, we explored novel ways to target NK-cell neoplasms by combining the clinically approved JAK inhibitor ruxolitinib with other targeted agents. We profiled 7 malignant NK-cell lines in drug sensitivity screens and identified that these exhibit differential drug sensitivities based on their genetic background. In short-term assays, various classes of drugs combined with ruxolitinib seemed highly potent. Strikingly, resistance to most of these combinations emerged r

SUBMITTER: Parri E 

PROVIDER: S-EPMC8045497 | biostudies-literature | 2021 Apr

REPOSITORIES: biostudies-literature